Athanor Capital, LP Immunovant, Inc. Transaction History

Athanor Capital, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$13.08 - $49.6 $175,520 - $665,582	-13,419 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$36.36 - $52.71 $174,564 - $253,060	4,801 Added 55.71%	13,419 $620,000
Q3 2020 Nov 16, 2020	SELL	$22.61 - $38.9 $174,323 - $299,919	-7,710 Reduced 47.22%	8,618 $303,000
Q2 2020 Aug 13, 2020	BUY	$13.87 - $28.44 $226,469 - $464,368	16,328 New	16,328 $398,000
Q1 2020 May 14, 2020	SELL	$8.36 - $17.13 $4.18 Million - $8.57 Million	-500,000 Closed	0 $0

Q4 2019 Feb 14, 2020	BUY	$10.02 - $16.4 $5.01 Million - $8.2 Million	500,000 New	500,000 $7.94 Million

214

81.3M

557K

704K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of Athanor Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Athanor Capital, LP with notifications on news.